Imaging With a New Agent That Finds a Cancer Protein Called HER2

Completed · Phase 1

Conditions studied: HER2-positive Carcinoma, HER2-positive Primary Malignancy

In brief

The purpose of this study is to test if an imaging agent called Zr-DFO-pertuzumab that finds HER2 proteins can be used to take pictures of HER2-positive cancer.

Key facts

Study ID

NCT03109977

Run by

Memorial Sloan Kettering Cancer Center

People needed

6

Starts

2017-03-31

Expected to finish

2018-04-12

Last updated by the study team

2018-04-17

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 21 years or greater
• Any biopsy proven HER2-positive malignancy. ASCO guidelines will be used to define HER2-positivity for breast cancer. Similar guidelines will be used for other cancer types as appropriate.
• At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment
• ECOG performance of 0-2

You may not qualify if…

• Life expectancy < 3 months
• Pregnancy or lactation
• Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.

Where it is running

• Memorial Slaon-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.